Skip to main content

Advertisement

SpringerLink
Log in

Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Tumor markers Ki67, TP53, and TP63 are common labels in the diagnosis of bladder cancer (BCa) around the world. The combination of those biomarkers may have advantages in predicting BCa prognosis and non-muscle-invasive bladder cancer (NMIBC) postoperative recurrence. We investigated the immunohistochemical profiles of 313 bladder cancer samples classified under the WHO/ISUP (2004) grading scale and the UICC-TNM (2002) classification. Then we investigated their predictive value in the tumor recurrence of 270 NMIBC patients after TURBT. Expression of Ki67 correlates with grade, stage, tumor size, and tumor numbers. Semiquantitative evaluation of TP53 correlates with grade and invasive conditions. The positive expression rate of TP63 correlated with tumor grade and stage. The combined effect of TP53 and Ki67 revealed a predictive value in NMIBC recurrence. However, the positive TP63 expression did not show any protective effect in NMIBC recurrence. The expression of TP53 and Ki67 could be used to predict the risk of NMIBC recurrence postoperatively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cordon-Cardo C et al. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl. 2008;8:154–65.

    Article  CAS  Google Scholar 

  2. Epstein JI, Amin VR, Reuter FK, et al. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. The Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435–48.

    Article  PubMed  CAS  Google Scholar 

  3. Larsson P, Wijkstrom H, Thorstenson A, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol. 2003;37:195–201.

    Article  PubMed  Google Scholar 

  4. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–203.

    Article  PubMed  Google Scholar 

  5. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21(4):690–6.

    Article  PubMed  Google Scholar 

  6. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999;161(5):1494–7.

    Article  PubMed  CAS  Google Scholar 

  7. Evans CP, Debruyne F, Payne H, et al. Bladder cancer: management and future directions. Eur Urol Suppl. 2007;6:365–73.

    Article  Google Scholar 

  8. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73–8.

    Article  PubMed  CAS  Google Scholar 

  9. Pruthi RS, Baldwin N, Bhalani V, et al. Conservative management of low risk superficial bladder tumors. J Urol. 2008;179(1):87–90.

    Article  PubMed  Google Scholar 

  10. Sylvester R, Oosterlinck W, van der Meijden A, et al. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol. 2000;37 Suppl 3:1–9.

    PubMed  Google Scholar 

  11. Evans C, Debruyne F, Payne H, et al. Bladder cancer: management and future directions. Eur Urol Suppl. 2006;6:365–73.

    Article  Google Scholar 

  12. Bryan RT, Zeegers MP, James ND, et al. Biomarkers in bladder cancer. BJU Int. 2010;105:608–13.

    Article  PubMed  CAS  Google Scholar 

  13. Sauter G, Algaba F, Amin M., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, eds. WHO classification of classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press, 2004, pp. 29–34.

  14. Sobin LH, Gospodariwicz M, Wittekind C. (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009; pp. 262–265.

  15. Wang L, Feng C, Ding G, et al. Relationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification. J BUON. 2013;18(2):420–4.

    PubMed  Google Scholar 

  16. Feng CC, Wang PH, Ding Q, Guan M, Zhang YF, Jiang HW, et al. Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol. 2013;31(2):241–6.

    Article  PubMed  CAS  Google Scholar 

  17. Feng C, Wu Z, Guo T, Jiang H, Guan M, Zhang Y, et al. BLCA-4 expression is related to MMP-9, VEGF, IL-1α and IL-8 in bladder cancer but not to PEDF. TNF-α or angiogenesis. Pathol Biol (Paris). 2012;60:e36–40.

    Article  CAS  Google Scholar 

  18. Feng CC, Wang PH, Guan M, Jiang HW, Wen H, Ding Q, et al. Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness. Folia Biol (Praha). 2011;57:242–7.

    CAS  Google Scholar 

  19. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5.

    Article  PubMed  Google Scholar 

  20. Montironi R, Mazzucchelli R, Colanzi P, et al. Improving interobserver agreement and certainly level in diagnosing and grading papillary urothelial neoplasms. Usefulness of a Bayesian belief network. Eur Urol. 2002;41:449–57.

    Article  PubMed  Google Scholar 

  21. Yurakh A, Ramos D, Calabuig-Frinas S, et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol. 2006;50:506–15.

    Article  PubMed  CAS  Google Scholar 

  22. Oosterhuis J, Schapers R, Janssen-Heijnen M, et al. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Clinical significance and comparison with other prognostic factors. Cancer. 2000;88:2598–605.

    Article  PubMed  CAS  Google Scholar 

  23. Wu T, Chen J, Lee Y, et al. The role of BCL-2, TP53 and Ki67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 2000;163:758–60.

    Article  PubMed  CAS  Google Scholar 

  24. Gonzalez-Campora R, Davalos-Casanova A, et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett. 2006;242:266–72.

    Article  PubMed  CAS  Google Scholar 

  25. Santos L, Amaro T, Pereira S, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. EJSO. 2003;29:74–80.

    Article  PubMed  CAS  Google Scholar 

  26. Mulder A, Van Hootegem J, Sylvester R, et al. Prognostic factors in bladder carcinoma: histological parameters and expression of a cell cycle related nuclear antigen (Ki67). J Pathol. 1992;166:37–43.

    Article  PubMed  CAS  Google Scholar 

  27. Vet JA, Bringuier PJ, Poddighe HF, et al. TP53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer. 1994;70:496–500.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  28. Erill N, Colomer A, Verdú M, et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol. 2004;13(4):217–23.

    Article  PubMed  CAS  Google Scholar 

  29. Comperat E, Camparo P, Haus R, et al. Immunohistochemical expression of p63, p53 and MIB-1in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch. 2006;448:319–24.

    Article  PubMed  CAS  Google Scholar 

  30. Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB-1 score, TP53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/pT1) bladder cancer: a prospective comparative study. Eur Urol. 1999;36:393–400.

    Article  PubMed  CAS  Google Scholar 

  31. Shariat S, Kim J, Raptidis G, et al. Association of p63 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140–5.

    Article  PubMed  Google Scholar 

  32. Friedrich M, Riethdorf S, Erbersdobler A, et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. J Urol. 1996;155:1754–7.

    Article  Google Scholar 

  33. Gontero P, Casetta G, Zitella A, et al. Evaluation of TP53 protein over expression, Ki67 proliferative activity and mitotic index as markers of tumor recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol. 2000;38:287–96.

    Article  PubMed  CAS  Google Scholar 

  34. Yang A, McKeon F, et al. P63 and P73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000;1:100–207.

    Article  CAS  Google Scholar 

  35. Park B, Lee S, Kim J, et al. Frequent alteration of p63 expression in human primary carcinomas. Cancer Res. 2000;60:3370–4.

    PubMed  CAS  Google Scholar 

  36. Urist M, Di Como C, Lu M, et al. Loss of p63 expression is associated with tumor progression in bladder. Am J Patho. 2002;161:1199–206.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Huashan Hospital, Fudan University, Shanghai, China

    Lujia Wang, Chenchen Feng, Guanxiong Ding, Qiang Ding, Haowen Jiang & Zhong Wu

  2. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China

    Zhongwen Zhou

Authors
  1. Lujia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chenchen Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guanxiong Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiang Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhongwen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haowen Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhong Wu.

Additional information

Lujia Wang and Chenchen Feng are equal contributors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, L., Feng, C., Ding, G. et al. Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer. Tumor Biol. 35, 2989–2995 (2014). https://doi.org/10.1007/s13277-013-1384-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1384-9

Keywords

Search

Navigation